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Abstract 
Background and research question:  Gliomas represent 43% of all solid intracranial 
tumours, of which glioblastomas have the poorest prognosis.  Recently, the human cytosolic 
branched-chain aminotransferase protein (hBCATc), which metabolises the branched-chain 
amino acids (BCAA), was identified as a biomarker and therapeutic target for glioblastomas 
carrying wild-type isocitrate dehydrogenase (IDH-WT) genes.  However, the clinical utility of 
the mitochondrial isoform, hBCATm, which also metabolises BCAAs, was not determined 
nor its potential role in predicting patient survival.   
Methods:  Glioblastomas, of grades II-IV, from 53 patients were graded by a 
neuropathologist, where the IDH and MGMT status were assessed.  Tumours positive for 
hBCATm, hBCATc and BCKDC were characterised using immunohistochemistry and 
Western blot analysis using antibodies specific to these proteins.   
Results:  Here, we report that in IDH-WT tumours, the expression of hBCATm is 
significantly increased (p=0.034) relative to IDH mutation gliomas, and significantly 
correlates with patient survival, on Kaplan-Meier analysis, where low hBCATm expression is 
a positive prognostic factor (p=0.003).  Moreover, increased hBCATm expression in these 
glioblastomas correlated with tumour grade indicating their role as a predictive biomarker of 
glioma progression.  Multiple banding was observed for the branched-chain α-keto acid 
dehydrogenase complex, which catalyses the committed step in BCAA metabolism, but a 
significant change in expression was absent (p=0.690).   
Conclusion:  Until now, IDH-WT glioblastomas have a uniformly poor prognosis, however 
we demonstrate for the first time that relatively low hBCATm may select for a better 
performing subset within this group and may represent a therapeutic target in these hard to 
treat patients. 
Keywords:  Glioblastomas, therapeutic target, biomarkers, branched-chain 
aminotransferase, hBCATm, hBCATc  
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Introduction 
Although histologically indistinguishable, glioblastomas vary in their clinical, genetic and 
epigenetic profiles (Ohgaki and Kleihues, 2013;Kreth et al., 2014).  Primary glioblastomas, 
which arise de novo, may show epidermal growth factor receptor (EGFR) amplification and 
PTEN mutations, compared with secondary glioblastomas that progress from lower grade 
astrocytomas, which occur in younger patients, and typically carry mutations including 
isocitrate dehydrogenase IDH1/2, which tend to be absent in primary glioblastomas (<5%) 
(Balss et al., 2008;Guo et al., 2011).  Although glioblastomas with IDH mutations are 
associated with an improved prognosis and a hypermethylated phenotype, hypermethylation 
of the O6-methylguanine-DNA methytransferase (MGMT) gene promoter can also be seen in 
primary glioblastomas in the absence of IDH mutations (Guo et al., 2011;Esteller et al., 
2000;Esteller et al., 2000).  Conv rsely, IDH-wild-type (IDH-WT) tumours that exhibit an 
increased expression of the cytosolic human branched-chain aminotransferase protein 
(hBCATc) are linked with a poor prognosis (Tönjes et al., 2013).  Tönjes and co-authors 
showed that increased expression of hBCATc supports tumour growth and highlighted it as a 
new therapeutic target for glioblastomas.   
The hBCATc protein is however one of two isoforms (the other, mitochondrial (hBCATm)) 
that can catalyse the transamination of the branched-chain amino acids (BCAA) followed by 
complete oxidation by the branched-chain α-keto acid dehydrogenase complex (BCKDC) 
(Conway and Hutson, 2015).
  
Like BCAT1 (gene encoding hBCATc), a significant up 
regulation of BCAT2 (gene encoding hBCATm) was reported in IDH-WT tumours (Tönjes et 
al., 2013).  However, hBCATm expression was not studied at the protein level nor assessed 
as a prognostic marker for patient survival.  It is important to consider hBCATm expression 
and indeed the expression of the BCKDC in IDH-WT tumours because their existence will 
also contribute to BCAA metabolism promoting tumour survival.  This is of relevance 
because, if hBCATc was considered the only contributor to BCAA metabolism and thus the 
sole therapeutic target, then if hBCATm expression was found to be increased in 
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glioblastomas it could potentially attenuate a hBCATc inhibitor.  Therefore, in light of this and 
other studies where expression of hBCATm is raised under proliferative conditions (Pérez-
Villaseñor et al., 2005) and our studies which show that hBCATm expression, more so than 
hBCATc, is significantly increased and correlates with Braak stage in Alzheimer’s disease 
(Hull et al., 2015;Hull et al.,2015) we examined the differential expression of hBCATm and 
BCKDC in IDH-WT and IDH mutation glioblastomas and determined if their expression 
correlated with patient survival.  Our interest also extends to the potential for these metabolic 
proteins to show value as biomarkers between tumour grades, offering increased clinical 
utility for these proteins.  
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Materials and methods 
Patient Samples 
The study was approved by the Brain Tumour Bank South West Research Ethics 
Committee, Bristol, UK.  For Western blot analysis, 64 glioma tumours with a range of sub-
types were compared for BCKDC, hBCATc, and hBCATm expression (Supplementary Table 
1).  For IHC 53 glioma cases were graded by Dr. Kurian, consultant neuropathologist at 
Southmead Hospital Neuropathology Department, Bristol, UK.  All glioma cases had a 
diagnosis from grade II to IV.   
IDH and MGMT analysis 
DNA was extracted from fresh, frozen tissue using the BioRobot EZ1 workstation (Qiagen).  
Sanger sequencing of the p.Arg132 region of IDH1 (codons 55 – 138) and p.Arg172 region 
of IDH2 (codons 151 – 179) was completed using a 3730 DNA analyser (Applied Bio- 
Systems).  Immunohistochemistry (IHC) was performed using standard techniques with the 
antibody clone H09 (Dianova), which specifically reacts with the isocitrate dehydrogenase 1 
(IDH1) R132H point mutation (1:10 dilution for 30 min at room temperature) in formalin-fixed 
tissue.  MGMT analysis was assessed by methylation sensitive PCR.  DNA samples 
underwent bisulphite modification, followed by PCR using the primers described by Estellier 
et al 2000 in a diplex reaction.  PCR products were separated on the Beckman Coulter CEQ 
8000 system. 
Immunohistochemistry 
Sections (3 µm in thickness) were taken onto 3-aminopropyltriethoxysilane coated adhesive 
slides and prepared for incubation with antibodies as previously described.10,12 Primary 
antibodies included: anti-hBCATm, 1:1000; anti-hBCATc, 1:6000; anti-BCKDC (ab126173, 
raised to the E1α subunit), 1:6000, incubated overnight (~20 hours) at room temperature.  
Standard IHC was performed as per Vectastain ABC and DAB substrate protocol, prior to 
immersion in copper sulphate (16 mM CuSO4.5H2O, 123 mM NaCl) for 4 minutes and 
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counterstained with Harris’s haematoxylin (25% Gill haematoxylin).  Sections were viewed, 
scored and imaged on a Nikon Eclipse 50i and 80i microscope. 
Scoring protocol 
Each image was scored based on the degree of DAB staining.  The sections were examined 
under a 20X objective and the degree of labelling designated on a semi-quantitative scale: 0 
= no staining, 1 = mild, 2 = moderate and 3 = intense staining.  Scoring of each slide was 
independently performed by 3 individuals, with the median score used to obtain consensus.  
The analysis was conducted blind to mutation status, grade and age at diagnosis of each 
patient.  The corresponding area of tissue was found with each of the antibodies in order to 
allow direct comparison of tumour cells.  Negative antibody controls, where primary antibody 
was replaced with PBS, were supplied by Frenchay Neuropathology Department.  
Western blot analysis  
For Western blot analysis, 250 mg of tissue was collected in RNase free tubes and 
homogenised as described in Hull et al., 2015a.  Primary antibody (anti-BCKDC, 1/5000; 
anti-hBCATc, 1/5000; anti-hBCATm, 1/5000; anti-tubulin 1/000, 1/10 000 anti-GAPDH, 1/10 
000) was prepared in 5% non-fat milk powder in TBST and incubated overnight (20 hours, 
4°C) prior to TBST washes.  Secondary antibody (1/5000) linked with HRP, was added for 1 
hour and then washed with TBST.  The positive bands were visualized using 
chemiluminescent HRP substrate.  GBX developer and fixer were used for 40 and 20 
seconds respectively.  Integrated area densitometry was carried out with ImageJ.  For re-
probing, membranes were incubated with 1 M NaOH (7 minutes) and washed in TBST.   
Statistical analysis  
Data validity checks and descriptive analyses were performed prior to inferential analyses.  
These preliminary analyses indicated good quality data, free from unusual or aberrant 
observations, on model fit in a Cox proportional hazards regression.  The strength of the 
association between BCKDC, hBCATc and hBCATm was quantified using Pearson’s 
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product moment correlation coefficient for linear association and for monotone association 
using the nonparametric Spearman’s rank correlation coefficient.  Both approaches gave the 
same statistical conclusions.  Differences in mean levels for each of BCKDC, hBCATm and 
hBCATc between IDH+ and IDH- was assessed using the robust independent samples t-test 
without assuming equality of variances (the Welch-Aspin test) and was triangulated using 
bootstrapping.  Both approaches gave the same statistical conclusions.  A two-group 
Kaplan-Meier analysis of overall survival (OS) using the Mantel Cox log-rank test to judge 
statistical significance was conducted using a median cut-point on each of BCKDC (median 
= 0.6), hBCATm (median = 0.40), and hBCATc (median = 0.40).  A two-group Kaplan-Meier 
analysis is robust to the presence of potentially influential observations.  In addition, a 
sensitivity analysis was also performed to ensure conclusions were robust to the choice of 
cut-point.   
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RESULTS 
All IDH-WT tumours examined have increased expression of the BCAA metabolic proteins 
relative to normal brain tissue (Hull et al., 2012).  Western blot analysis has demonstrated 
that in IDH–WT tumours there was a significant increase in the expression of hBCATm 
(p=0.036) and hBCATc (p=0.007) relative to IDH mutation glioblastomas (Figure 1A and B).  
This increase in hBCAT expression was supported using IHC analysis (Figure 1C).  
Although several banding patterns for BCKDC are evident in these gliomas, where 
combinations of 50 and 70 kDa proteins existed, the overall expression between IDH-WT 
and IDH1 did not show a significant difference (Figure 1A, B and C).  Interestingly, 
substantive expression of BCKDC is evident in IDH1 mutation tumours even though hBCAT 
expression is largely absent. 
Statistically, hBCATm and hBCATc have a high positive correlation coefficient (r = 0.625, p < 
0.001).  However, hBCATm is more specific that hBCATc, when considering Overall 
Survival.   A Kaplan-Meier survival curve (Figure 2) and log-rank tests demonstrated that the 
predominant factor effecting overall survival is IDH status (Figure 2A), with IDH mutation 
positive gliomas associated with significantly better survival (p=0.005).  Additionally, for all 
combinations of IDH-WT gliomas (Grade 2, 3 and 4), those expressing low hBCATm 
(median split) are associated with better overall survival (Figure 2B p=0.003).  Moreover, in 
the Grade 4 only population, and exclusively considering those IDH-WT, a similar Kaplan-
Meier curve (Figure 2C) and log-rank analysis shows that low hBCATm is significantly 
associated with better overall survival (p=0.043).  The overall summary from these analyses 
is that hBCATm retains clinical utility across all data.  Neither hBCATc nor BCKDC had a 
statistical effect on patient survival (p=0.971 and 0.642, respectively).   
Moreover, between tumour grades we observed a significant increase in hBCATm 
expression (p=0.010), indicating that as expression of hBCAT increases prognosis is poorer 
(Figure 3).  Multiple banding patterns for hBCATm are also reported for anaplastic 
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oligodendroglioma indicating that different isoforms of hBCATm are prominently expressed 
in these tumour types (Figure 4).  In some IDH1 mutation tumours positive hBCATc 
expression was observed, which was previously considered to be absent in these tumours 
(data not shown).  Also, less expression of the BCKDC upper band at 70 kDa is observed 
between the stage III AO tumours and the stage IV GBM tumours (observation).   
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DISCUSSION 
Despite aggressive treatment with combined radiochemotherapy and cytoreductive surgery, 
glioblastomas still have a poor prognosis, highlighting the need for new therapeutic targets 
and prognostic indicators.  However, there is a large degree of variation, with marked 
differences in survival time attributed to the mutation status of key genetic markers, two of 
which are IDH and MGMT status (Nikiforova et al., 2011).  IDH status and methylation of 
genes is strongly associated with prognosis.  Hypermethylation of the MGMT repair enzyme 
leads to epigenetic gene silencing, preventing the transcription of MGMT, and increasing 
tumour susceptibility to DNA damage by alkylating agents such as temozolomide, thus 
improving patient outcome (Esteller et al., 2000; Esteller 2000).  Improved prognosis is also 
reported for patients with a mutation in the IDH1 isoform.  There are three isoforms of IDH, 
IDH1 is cytosolic and IDH2 and IDH3 are mitochondrial (Guo et al., 2011).  IDH1 and IDH2 
are NADP+-dependent enzymes that, under normal physiological conditions, catalyse the 
oxidative carboxylation of isocitrate to α-ketoglutarate as part of the TCA cycle (Reitman et 
al., 2011).  In some gliomas, IDH has a point mutation resulting in a single amino acid 
substitution at arginine-132 in IDH1 and arginine-140 in IDH2 (Gross et al., 2010).  Both 
point mutations result in a functional enzyme that produces 2-hydroxyglutarate (2HG) (Gross 
et al., 2010;Dang et al., 2010) (Figure 5).  Accumulation of 2HG causes methylation of 
histones within chromatin, preventing uncoiling and can prevent growth by impairment of 
cellular differentiation (Lu et al., 2012).  In gliomas with IDH-WT profiles there is frequently 
an amplification of EGFR (Hartmann et al., 2010), which is associated with increased 
proliferation and radiotherapy resistance (Nakamura 2007).  For survival, these tumours 
have hypermetabolic rates where glucose and glutamine are key metabolic fuels.  More 
recently, an increased expression of hBCATc, a key metabolic protein, was associated with 
IDH-WT tumours (Tonjes et al., 2013).  In this study, hBCATc metabolism was shown to 
contribute to cell proliferation and in IDH1 mutation models, BCAT1 was shown to be 
hypermethylated resulting in decreased expression, indicating a direct role for hBCATc in 
tumorgenesis, and a potential therapeutic target (Tonjes et al., 2013).   
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Under normal physiological conditions, the hBCAT isoforms show both tissue and cell 
specific expression (Hull et al., 2012), which makes their co-expression in gliomas most 
unusual, highlighting new regulatory mechanisms for the BCAT genes under pathogenic 
conditions.  Here, we report that the mitochondrial isoform, hBCATm, was also significantly 
(p=0.036) increased in IDH-WT tumours and more importantly is a negative predictor of 
patient survival in IDH-WT glioblastomas (p=0.003) and also in grade IV tumours alone 
(p=0.043).  This is significant because if hBCATc alone was inhibited i.e. the sole BCAA 
metabolic target, then the activity of hBCATm might hypothetically supersede that of 
hBCATc attenuating the impact of a targeted therapeutic.  As expression of both hBCATs is 
significantly increased in IDH-WT tumours, we predict that this will generate high 
concentrations of BCKAs and glutamate, supporting the hypothesis that increased BCKA 
production contributes to tumour growth and proliferation, dependent on the activity of the 
BCKDC.  Glutamate, also a product of BCAA metabolism, is a precursor for glutamine 
synthesis, a major nutrient for tumorigenesis.  Numerous metabolic studies have supported 
a BCAA/BCKA shuttle between neuronal and astrocytic cells in rat and cell culture models 
(Leith et al., 2001;Sweatt et al., 2004), indicating that in IDH1-WT tumours, a role exists for 
glutamate and glutamine metabolism, which will be critical for brain neurotransmitter 
metabolism and detoxification.  Increased concentrations of glutamate has already been 
shown to occur in gliomas, providing multiple benefits to tumour mass, including the increase 
in the growth rate of tumour cells (Takano et al., 2001), and an increased ability to invade 
the surrounding tissue by increasing cellular motility (Lyons et al., 2007).  Glutamate release 
also destroys neuronal cells creating a path for tumour growth (Sontheimer et al., 2003).  
Release of glutamate in exchange for cysteine is controlled by the system xc- cysteine 
glutamine exchanger.  The exchanger functions to generate glutathione (GSH) with 
increased glutamate production leading to a rise in GSH concentration (De Groot et al., 
2011).  In tumours, increased GSH is considered to protect against reactive oxygen species 
further supporting tumour survival.  Therefore, increased hBCAT expression, as reported 
here, would result in neurological damage by accumulation of glutamate, increased 
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invasiveness and free radical protection through increased glutamate production, altogether 
of benefit to tumour survival. 
Clearly, expression of hBCATc in IDH-WT tumours presents as a very attractive target for 
new therapies.  However, this new data indicates that with increased hBCATm in IDH-WT 
tumours one must also consider how their expression will impact tumour growth and 
survival.  Moreover, these studies are the first to illustrate that as the tumour progresses 
from grade II to grade IV the expression of both isoforms increases, supporting their role as 
new prognostic markers and indicators of patient survival.  
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 Table 1:  Patient details, IDH/MGMT of sample Glioblastomas  
Patient 
number
Age at 
diagnosis
Diagnosis Grade Gender IDH Status
MGMT 
status
1 43 Glioblastoma IV Male IDH- U
2 44 Glioblastoma IV Male IDH- U
3 61 Glioblastoma IV Male IDH- U
4 68 Glioblastoma IV Male IDH- M
5 64 Glioblastoma IV Male IDH+ M
6 46 Glioblastoma IV Male IDH+ M
7 35 Glioblastoma IV Male IDH+ M
8 38 Glioblastoma IV Female IDH+ M
9 26 Anaplastic astrocytoma III Female IDH+ M
10 25 Anaplastic astrocytoma III Male IDH+ U
11 20 Anaplastic astrocytoma III Male IDH+ U
12 58 Anaplastic astrocytoma III Male IDH- M
13 67 Anaplastic astrocytoma III Male IDH- U
14 51 Anaplastic astrocytoma III Female IDH- M
15 61 Oligodendroglioma II Male IDH+ M
16 44 Oligo-Astrocytoma II Female IDH- U
17 69 Anaplastic Oligodendroglioma III Male IDH- U
18 54 Anaplastic Oligodendroglioma III Male IDH+ M
19 57 Anaplastic Oligodendroglioma III Female IDH- M
20 46 Anaplastic Oligodendroglioma III Female IDH- M
21 46 Anaplastic Oligodendroglioma III Female IDH- M
22 63 Glioblastoma IV Female IDH- UK
23 39 Glioblastoma IV Male IDH- U
24 28 Glioblastoma IV Female IDH+ M
25 32 Oligo-Astrocytoma II Female IDH+ M
26 73 Anaplastic astrocytoma II Male IDH- M
27 44 Anaplastic astrocytoma III Male IDH- U
28 54 Glioblastoma IV Female IDH- U
29 47 Glioblastoma IV Male IDH- M
30 68 Glioblastoma IV Male IDH- M
31 72 Glioblastoma IV Female IDH- M
32 56 Glioblastoma IV Male IDH- U
33 67 Anaplastic Astrocytoma III Male IDH- U
34 66 Glioblastoma IV Male IDH- M
35 51 Glioblastoma IV Male IDH- M
36 43 Glioblastoma IV Female IDH- M
37 71 Glioblastoma IV Female IDH- M
38 55 Glioblastoma IV Female UK M
39 68 Glioblastoma IV Male IDH- U
40 64 Glioblastoma IV Female IDH- M
41 66 Glioblastoma IV Female IDH- M
42 48 Glioblastoma IV Male IDH- U
43 61 Glioblastoma IV Male IDH- U
44 58 Glioblastoma IV Female IDH- U
45 57 Glioblastoma IV Female IDH- M
46 65 Glioblastoma IV Female IDH- M
47 52 Glioblastoma IV Male IDH- M
48 74 Glioblastoma IV Female IDH- U
49 53 Glioblastoma IV Male IDH- U
50 58 Glioblastoma IV Male IDH- M
51 34 Oligo-Astrocytoma II Male IDH+ M
52 24 Oligo-Astrocytoma II Female IDH+ M
53 29 Oligo-Astrocytoma II Female IDH+ M
54 39 Diffuse Astrocytoma II Female IDH+ M
55 49 Oligo-Astrocytoma II Female IDH+ M
56 UK Diffuse Astrocytoma II UK IDH+ M
57 UK Diffuse Astrocytoma II UK IDH+ M
58 50 Oligo-Astrocytoma II Female IDH+ M
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FIGURE LEGENDS 
 
Figure. 1.  Increased hBCAT expression in IDH-WT gliomas relative to IDH1 
tumours.  Western blot analysis and immunohistochemistry was used to evaluate 
the expression of BCKDC, hBCATm and hBCATc in IDH-WT and IDH1 mutation 
gliomas.  Panel A: Patient details and Western blot analysis of glioma homogenates.  
The density of each band was measured using ImageJ
TM
 software and analysed for 
significance using a one-way ANOVA test in Minitab™ (n=55).  Panel B: Panels 
show interquartile range (box) sample variability (whiskers) and the median 
(horizontal line within the interquartile range) of Western blot analysis for BCKDC, 
hBCATm and hBCATc relative to α-tubulin.  Statistical analysis reveals a significant 
increase in hBCATm (p=0.036) and hBCATc (p=0.007) protein expression in IDH-WT 
gliomas compared to IDH mutation gliomas.  Panel C: BCKDC, hBCATm, hBCATc 
staining of glioma sections, where increased staining was observed for hBCATm and 
hBCATc for IDH-WT relative to IDH mutation gliomas (n=51).  Magnification for all 
sections, X20.  Abbreviations: F – female; M – male; Me – methylated; MGMT – 
methylguanine-DNA methytransferase methylation; U – unmethylated. 
 
Figure. 2.  Kaplan Meier analysis for IDH status and hBCATm expression.  
Statistics were calculated from Log rank Mantel-Cox analysis.  Panel A: Cumulative 
survival of IDH status demonstrates significantly increased rate of survival in IDH 
mutation gliomas compared to IDH-WT (p=0.005) (n=47).  Panel B: Cumulative 
survival of hBCATm expression in IDH-WT patients (including grades 2, 3 and 4): 
demonstrates significantly increased rate of survival in low (median split) hBCATm 
expressing gliomas (p=0.003) (n=35).  Panel C: Cumulative survival of hBCATm 
expression in IDH-WT patients (grade 4 only) demonstrates significantly increased 
rate of survival in low (median split) hBCATm expressing gliomas (p=0.043) (n=24).   
 
Figure. 3.  hBCAT expression increases with tumour grade.  Western blot 
analysis of BCKDC, hBCATm and hBCATc in glioma samples, grade 2-4.  There is a 
significant increase in hBCATm (p=0.010) with increasing grade, where a trend for 
increased hBCATc is also observed (n=55).  Abbreviations: F – female; M – male; Me 
– methylated; MGMT – methylguanine-DNA methytransferase methylation; O1 – 
Oligodendroglioma; O2 – Oligo-Astrocytoma; U – unmethylated. 
 
Figure. 4.  Multiple banding for hBCATm in Oligodendric gliomas and 
Anaplastic oligodendrogliomas.  Western blot analysis of BCKDC, hBCATm and 
hBCATc in IDH-WT and IDH mutation glioma samples.  Abbreviations: F – female; M 
– male; Me – methylated; MGMT – methylguanine-DNA methytransferase 
methylation; O1 – Oligodendroglioma; O2 – Oligo-Astrocytoma; U – unmethylated.   
 
Figure 5.  IDH-WT and IDH1 mutation metabolism of citrate, linked with BCAA 
metabolism.  A.  IDH-WT catalyses the oxidative carboxylation of isocitrate to α-
ketoglutarate as part of the TCA cycle.  B.  In glioblastomas with IDH mutation the 
product of catalysis is 2-hydroxyglutarate, accumulation of which causes methylation 
of histones within DNA, ultimately impairing differentiation.  C.  In IDH-WT tumours 
increased hBCAT expression contributes to tumour survival and neurotoxicity of 
neighbouring healthy brain cells. 
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Table 1. Glioma cases used in immunohistochemical and Western blot analysis 
of BCKD, hBCATc and hBCATm.  All cases were from the South West Brain 
Tumour Bank (Southmead Hospital) and had no significant comorbidities (such as 
Vascular dementia or Parkinson’s disease).  Abbreviations: M – methylated; MGMT – 
methylguanine-DNA methytransferase methylation; U – unmethylated; UK - 
unknown. 
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Figure 3 
 
 
 
Page 20 of 23Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
21 | P a g e  
 
 
Figure 4 
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Figure 5 
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